Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

Published:2014-10-07 Issue:1 Volume:64 Page:61-73
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Balasa Balaji,Yun Rui,Belmar Nicole A.,Fox Melvin,Chao Debra T.,Robbins Michael D.,Starling Gary C.,Rice Audie G.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-014-1610-3/fulltext.html

Reference40 articles.

1. Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364:1046–1060

2. Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC (2011) Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 154:745–754

3. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM (2008) Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112:4445–4451

4. Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, Mendy D, Lopez-Girona A, Tran T, Sapinosa L, Fang W, Xu S, Hampton G, Bartlett JB, Schafer P (2010) Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 10:155–167

5. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69:56–63

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy;Trends in Molecular Medicine;2024-08

2. Promising immunotherapeutic approaches for primary effusion lymphoma;Exploration of Targeted Anti-tumor Therapy;2024-06-26

3. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials;Hematological Oncology;2024-05-31

4. Therapeutic progress in relapsed/refractory multiple myeloma;Annals of Hematology;2024-04-13

5. Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma;Journal for ImmunoTherapy of Cancer;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3